Center for Biosimilars

Biosimilar Tocilizumab Shows Cost-Effectiveness Advantage in Spanish RA Population

Biosimilar tocilizumab proves to be a cost-effective treatment for rheumatoid arthritis in Spain, enhancing access to ...
Center for Biosimilars

Stable Treatment Persistence in RA After Etanercept Biosimilar Introduction in Australia

Australia's adoption of etanercept biosimilars enhances access to rheumatoid arthritis treatments, maintaining treatment ...
Center for Biosimilars

Eye on Pharma: Europe and MENA Region See Expanding Biosimilar Pipelines

Major advancements in biosimilars emerge in Europe and Middle East and North Africa (MENA) region, enhancing patient access ...
Center for Biosimilars

Biosimilars Drive Savings and Access, Yet Looming Development Gap Threatens Future

Biosimilars and generics drive significant health care savings, yet a concerning lack of biosimilar development for biologics ...
Center for Biosimilars

The Top 5 Biosimilar Articles for the Week of September 22

Number 5: The FDA has approved Bosaya (denosumab-kyqq) and Aukelso (denosumab-kyqq), the sixth pair of denosumab biosimilars to receive the green light from the agency. The approvals, granted to ...